{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:06:33Z","timestamp":1789070793361,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hemophilia A is a monogenic disease with a blood clotting factor VIII (FVIII) deficiency caused by mutation in the factor VIII (<jats:italic>F8)<\/jats:italic> gene. Current and emerging treatments such as FVIII protein injection and gene therapies via AAV-delivered <jats:italic>F8<\/jats:italic> transgene in an episome are costly and nonpermanent. Here, we describe a CRISPR\/Cas9-based <jats:italic>in vivo<\/jats:italic> genome editing method, combined with non-homologous end joining, enabling permanent chromosomal integration of a modified human B domain deleted-F8 (<jats:italic>BDD-F8)<\/jats:italic> at the albumin (<jats:italic>Alb<\/jats:italic>) locus in liver cells. To test the approach in mice, C57BL\/6 mice received tail vein injections of two vectors, AAV8-SaCas9-gRNA, targeting <jats:italic>Alb<\/jats:italic> intron 13, and AAV8-<jats:italic>BDD-F8<\/jats:italic>. This resulted in <jats:italic>BDD-F8<\/jats:italic> insertion at the <jats:italic>Alb<\/jats:italic> locus and FVIII protein expression in the liver of vector-, but not vehicle-, treated mice. Using this approach in hemophilic mice, <jats:italic>BDD-F8<\/jats:italic> was expressed in liver cells as functional human FVIII, leading to increased plasma levels of FVIII and restoration of blood clotting properties in a dose-dependent manor for at least 7 months, with no detectable liver toxicity or meaningful off-target effects. Based on these findings, our <jats:italic>BDD-F8<\/jats:italic> genome editing approach may offer an efficacious, long-term and safe treatment for patients with hemophilia A.<\/jats:p>","DOI":"10.1038\/s41598-019-53198-y","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T11:03:11Z","timestamp":1573729391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII"],"prefix":"10.1038","volume":"9","author":[{"given":"Hainan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-912X","authenticated-orcid":false,"given":"Mi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avital","family":"Gilam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivka","family":"Afrikanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Gluzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Jie","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby Yanru","family":"Chen-Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"53198_CR1","first-page":"992","volume":"54","author":"P Smejkal","year":"2008","unstructured":"Smejkal, P., Matyskova, M. & Penka, M. [Hemophilia]. Vnitr Lek 54, 992\u2013999 (2008).","journal-title":"Vnitr Lek"},{"key":"53198_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1055\/s-0032-1326786","volume":"38","author":"MD Carcao","year":"2012","unstructured":"Carcao, M. D. The diagnosis and management of congenital hemophilia. Semin Thromb Hemost 38, 727\u2013734, https:\/\/doi.org\/10.1055\/s-0032-1326786 (2012).","journal-title":"Semin Thromb Hemost"},{"key":"53198_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1365-2516.2009.02127.x","volume":"16","author":"JS Stonebraker","year":"2010","unstructured":"Stonebraker, J. S., Bolton-Maggs, P. H., Soucie, J. M., Walker, I. & Brooker, M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 16, 20\u201332, https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02127.x (2010).","journal-title":"Haemophilia"},{"key":"53198_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jth.12412","volume":"12","author":"T Shahani","year":"2014","unstructured":"Shahani, T. et al. Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J Thromb Haemost 12, 36\u201342, https:\/\/doi.org\/10.1111\/jth.12412 (2014).","journal-title":"J Thromb Haemost"},{"key":"53198_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bcp.2011.03.015","volume":"82","author":"RG Schaub","year":"2011","unstructured":"Schaub, R. G. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol 82, 91\u201398, https:\/\/doi.org\/10.1016\/j.bcp.2011.03.015 (2011).","journal-title":"Biochem Pharmacol"},{"key":"53198_CR6","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1111\/jth.12750","volume":"12","author":"ME Fomin","year":"2014","unstructured":"Fomin, M. E., Togarrati, P. P. & Muench, M. O. Progress and challenges in the development of a cell-based therapy for hemophilia A. J Thromb Haemost 12, 1954\u20131965, https:\/\/doi.org\/10.1111\/jth.12750 (2014).","journal-title":"J Thromb Haemost"},{"key":"53198_CR7","first-page":"223","volume":"18","author":"JM Holden","year":"1995","unstructured":"Holden, J. M. An overview of common bleeding disorders. J Intraven Nurs 18, 223\u2013230 (1995).","journal-title":"J Intraven Nurs"},{"key":"53198_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I","volume":"59","author":"JM Soucie","year":"1998","unstructured":"Soucie, J. M., Evatt, B. & Jackson, D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 59, 288\u2013294 (1998).","journal-title":"Am J Hematol"},{"key":"53198_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2165\/11585340-000000000-00000","volume":"71","author":"T Wong","year":"2011","unstructured":"Wong, T. & Recht, M. Current options and new developments in the treatment of haemophilia. Drugs 71, 305\u2013320, https:\/\/doi.org\/10.2165\/11585340-000000000-00000 (2011).","journal-title":"Drugs"},{"key":"53198_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12288-012-0209-0","volume":"30","author":"HE Castro","year":"2014","unstructured":"Castro, H. E., Briceno, M. F., Casas, C. P. & Rueda, J. D. The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review. Indian J Hematol Blood Transfus 30, 1\u201311, https:\/\/doi.org\/10.1007\/s12288-012-0209-0 (2014).","journal-title":"Indian J Hematol Blood Transfus"},{"key":"53198_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-24","volume":"7","author":"M Franchini","year":"2012","unstructured":"Franchini, M. & Mannucci, P. M. Past, present and future of hemophilia: a narrative review. Orphanet J. Rare Dis. 7, 24, https:\/\/doi.org\/10.1186\/1750-1172-7-24 (2012).","journal-title":"Orphanet J. Rare Dis."},{"key":"53198_CR12","unstructured":"Konkle, B. A., Nakaya Fletcher, H. H. & Hemophilia A. S. In: Pagon, R. A., Adam, M. P., Ardinger, H. H. et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1404\/ (2017)."},{"key":"53198_CR13","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","volume":"379","author":"E Berntorp","year":"2012","unstructured":"Berntorp, E. & Shapiro, A. D. Modern haemophilia care. Lancet 379, 1447\u20131456, https:\/\/doi.org\/10.1016\/S0140-6736(11)61139-2 (2012).","journal-title":"Lancet"},{"key":"53198_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/17474086.2016.1182859","volume":"9","author":"P Ward","year":"2016","unstructured":"Ward, P. & Walsh, C. E. Current and future prospects for hemophilia gene therapy. Expert Rev Hematol 9, 649\u2013659, https:\/\/doi.org\/10.1080\/17474086.2016.1182859 (2016).","journal-title":"Expert Rev Hematol"},{"key":"53198_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jhep.2016.05.012","volume":"65","author":"D D\u2019Avola","year":"2016","unstructured":"D\u2019Avola, D. et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol 65, 776\u2013783, https:\/\/doi.org\/10.1016\/j.jhep.2016.05.012 (2016).","journal-title":"J Hepatol"},{"key":"53198_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12, 342\u2013347, https:\/\/doi.org\/10.1038\/nm1358 (2006).","journal-title":"Nat Med"},{"key":"53198_CR17","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani, A. C. et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371, 1994\u20132004, https:\/\/doi.org\/10.1056\/NEJMoa1407309 (2014).","journal-title":"N Engl J Med"},{"key":"53198_CR18","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani, A. C. et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365, 2357\u20132365, https:\/\/doi.org\/10.1056\/NEJMoa1108046 (2011).","journal-title":"N Engl J Med"},{"key":"53198_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Z Wu","year":"2010","unstructured":"Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol Ther 18, 80\u201386, https:\/\/doi.org\/10.1038\/mt.2009.255 (2010).","journal-title":"Mol Ther"},{"key":"53198_CR20","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/blood.V81.11.2925.2925","volume":"81","author":"DD Pittman","year":"1993","unstructured":"Pittman, D. D. et al. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 81, 2925\u20132935 (1993).","journal-title":"Blood"},{"key":"53198_CR21","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1182\/blood.V95.5.1594.005k34_1594_1599","volume":"95","author":"H Chao","year":"2000","unstructured":"Chao, H., Mao, L., Bruce, A. T. & Walsh, C. E. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 95, 1594\u20131599 (2000).","journal-title":"Blood"},{"key":"53198_CR22","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","volume":"121","author":"J McIntosh","year":"2013","unstructured":"McIntosh, J. et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 121, 3335\u20133344, https:\/\/doi.org\/10.1182\/blood-2012-10-462200 (2013).","journal-title":"Blood"},{"key":"53198_CR23","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan, S. et al. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N Engl J Med 377, 2519\u20132530, https:\/\/doi.org\/10.1056\/NEJMoa1708483 (2017).","journal-title":"N Engl J Med"},{"key":"53198_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00439-016-1699-x","volume":"135","author":"CY Park","year":"2016","unstructured":"Park, C. Y., Lee, D. R., Sung, J. J. & Kim, D. W. Genome-editing technologies for gene correction of hemophilia. Hum Genet 135, 977\u2013981, https:\/\/doi.org\/10.1007\/s00439-016-1699-x (2016).","journal-title":"Hum Genet"},{"key":"53198_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DB Cox","year":"2015","unstructured":"Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat Med 21, 121\u2013131, https:\/\/doi.org\/10.1038\/nm.3793 (2015).","journal-title":"Nat Med"},{"key":"53198_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrg3686","volume":"15","author":"H Kim","year":"2014","unstructured":"Kim, H. & Kim, J. S. A guide to genome engineering with programmable nucleases. Nat Rev Genet 15, 321\u2013334, https:\/\/doi.org\/10.1038\/nrg3686 (2014).","journal-title":"Nat Rev Genet"},{"key":"53198_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.mimet.2018.03.004","volume":"148","author":"G Gobert","year":"2018","unstructured":"Gobert, G. et al. Droplet digital PCR improves absolute quantification of viable lactic acid bacteria in faecal samples. J Microbiol Methods 148, 64\u201373, https:\/\/doi.org\/10.1016\/j.mimet.2018.03.004 (2018).","journal-title":"J Microbiol Methods"},{"key":"53198_CR28","first-page":"430","volume":"13","author":"CW Pratt","year":"1992","unstructured":"Pratt, C. W. & Monroe, D. M. Microplate coagulation assays. Biotechniques 13, 430\u2013433 (1992).","journal-title":"Biotechniques"},{"key":"53198_CR29","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.1111\/hae.12484","volume":"20","author":"ES Molina","year":"2014","unstructured":"Molina, E. S., Fujita, A., Sogayar, M. C. & Demasi, M. A. A quantitative and humane tail bleeding assay for efficacy evaluation of antihaemophilic factors in haemophilia A mice. Haemophilia 20, e392\u2013398, https:\/\/doi.org\/10.1111\/hae.12484 (2014).","journal-title":"Haemophilia"},{"key":"53198_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/hae.12076","volume":"19","author":"S Pahl","year":"2013","unstructured":"Pahl, S. et al. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile. Haemophilia 19, 392\u2013398, https:\/\/doi.org\/10.1111\/hae.12076 (2013).","journal-title":"Haemophilia"},{"key":"53198_CR31","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","volume":"117","author":"NJ Ward","year":"2011","unstructured":"Ward, N. J. et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood 117, 798\u2013807, https:\/\/doi.org\/10.1182\/blood-2010-05-282707 (2011).","journal-title":"Blood"},{"key":"53198_CR32","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2012-10-464164","volume":"121","author":"JI Siner","year":"2013","unstructured":"Siner, J. I. et al. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood 121, 4396\u20134403, https:\/\/doi.org\/10.1182\/blood-2012-10-464164 (2013).","journal-title":"Blood"},{"key":"53198_CR33","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1093\/nar\/gkw064","volume":"44","author":"X He","year":"2016","unstructured":"He, X. et al. Knock-in of large reporter genes in human cells via CRISPR\/Cas9-induced homology-dependent and independent DNA repair. Nucleic Acids Res 44, e85, https:\/\/doi.org\/10.1093\/nar\/gkw064 (2016).","journal-title":"Nucleic Acids Res"},{"key":"53198_CR34","unstructured":"COSMID: CRISPR Search with Mismatches, Insertions and\/or Deletions, http:\/\/crispr.bme.gatech.edu"},{"key":"53198_CR35","unstructured":"World-Federation-of-Hemophilia. Special Issue: Invited presentation summaries and abstracts of the WFH, https:\/\/onlinelibrary.wiley.com\/toc\/13652516\/24\/S5 (2018)."},{"key":"53198_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04625-5","volume":"7","author":"T Ohmori","year":"2017","unstructured":"Ohmori, T. et al. CRISPR\/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. Sci Rep 7, 4159, https:\/\/doi.org\/10.1038\/s41598-017-04625-5 (2017).","journal-title":"Sci Rep"},{"key":"53198_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40272-018-0307-z","volume":"20","author":"RCR Ljung","year":"2018","unstructured":"Ljung, R. C. R. Prevention and Management of Bleeding Episodes in Children with Hemophilia. Paediatr Drugs 20, 455\u2013464, https:\/\/doi.org\/10.1007\/s40272-018-0307-z (2018).","journal-title":"Paediatr Drugs"},{"key":"53198_CR38","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1002\/jmv.23818","volume":"86","author":"J Mimuro","year":"2014","unstructured":"Mimuro, J. et al. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals. J Med Virol 86, 1990\u20131997, https:\/\/doi.org\/10.1002\/jmv.23818 (2014).","journal-title":"J Med Virol"},{"key":"53198_CR39","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","volume":"126","author":"R Sharma","year":"2015","unstructured":"Sharma, R. et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 126, 1777\u20131784, https:\/\/doi.org\/10.1182\/blood-2014-12-615492 (2015).","journal-title":"Blood"},{"key":"53198_CR40","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31, 822\u2013826, https:\/\/doi.org\/10.1038\/nbt.2623 (2013).","journal-title":"Nat Biotechnol"},{"key":"53198_CR41","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nmeth.3408","volume":"12","author":"V Iyer","year":"2015","unstructured":"Iyer, V. et al. Off-target mutations are rare in Cas9-modified mice. Nat Methods 12, 479, https:\/\/doi.org\/10.1038\/nmeth.3408 (2015).","journal-title":"Nat Methods"},{"key":"53198_CR42","doi-asserted-by":"publisher","first-page":"e1007503","DOI":"10.1371\/journal.pgen.1007503","volume":"14","author":"V Iyer","year":"2018","unstructured":"Iyer, V. et al. No unexpected CRISPR-Cas9 off-target activity revealed by trio sequencing of gene-edited mice. PLoS Genet 14, e1007503, https:\/\/doi.org\/10.1371\/journal.pgen.1007503 (2018).","journal-title":"PLoS Genet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53198-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53198-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53198-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:00:26Z","timestamp":1671292826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53198-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53198"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53198-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"8 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors except for L.K., H.C. and M.S. are employees of Applied StemCell, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16838"}}